Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
Clinical Pharmacology & Therapeutics – August 24, 2017
Source: OpenAlex
Summary
Compelling evidence points to the therapeutic promise of psychedelics in medicine. Beyond psilocybin, a wide variety of hallucinogenic agents are being investigated in drug studies, often involving chemical synthesis and alkaloids. While pharmacology explores their potential, marketing any psychotomimetic – a substance that can induce an illusion of psychosis – faces formidable regulatory hurdles. Unlocking these compounds' benefits requires navigating complex approval processes.
Abstract
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.